Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 7 Univariate analysis of the expression of metabolism-related proteins in breast cancers and disease-free survival or overall survival by logrank test a

From: Metabolic interaction between cancer cells and stromal cells according to breast cancer molecular subtype

Immunohistochemical factors Number of patients/ recurrence/death Disease-free survival Overall survival
Mean survival(95% CI), months P-value Mean survival (95% CI), months P-value
Glut-1 in tumor    0.010   0.023
 Negative 504/37/37 128 (125 to 131)   131 (128 to 134)  
 Positive 236/32/30 119 (112 to 126)   123 (118 to 128)  
Glut-1 in stroma    n/a   n/a
 Negative 724/69/67 n/a   n/a  
 Positive 16/0/0 n/a   n/a  
CAIX in tumor    0.740   0.222
 Negative 520/49/45 126 (122 to 130)   130 (127 to 132)  
 Positive 220/20/22 108 (102 to 113)   123 (117 to 130)  
CAIX in stroma    0.927   0.496
 Negative 627/59/56 125 (122 to 129)   129 (126 to 132)  
 Positive 113/10/11 103 (98 to 108)   116 (109 to 123)  
ATP synthase in tumor    0.506   0.936
 Negative 30/4/3 102 (90 to 114)   129 (117 to 141)  
 Positive 710/65/64 125 (122 to 129)   128 (126 to 131)  
ATP synthase in stroma    0.783   0.398
 Negative 570/53/50 125 (121 to 129)   129 (126 to 132)  
 Positive 170/16/17 118 (112 to 124)   122 (115 to 128)  
Glutaminase in tumor    0.323   0.164
 Negative 219/24/25 123 (117 to 128)   126 (120 to 131)  
 Positive 521/45/42 126 (122 to 130)   130 (127 to 133)  
Glutaminase in stroma    0.554   0.596
 Negative 495/49/48 123 (119 to 128)   128 (125 to 131)  
 Positive 245/20/19 127 (121 to 132)   128 (124 to 133)  
BNIP3 in tumor    0.004   0.426
 Negative 504/59/50 123 (119 to 127)   128 (124 to 131)  
 Positive 236/10/17 123 (119 to 127)   131 (126 to 135)  
BNIP3 in stroma    0.191   0.973
 Negative 700/68/64 125 (121 to 128)   128 (126 to 131)  
 Positive 40/1/3 116 (111 to 121)   121 (112 to 129)  
MCT4 in tumor    0.550   0.451
 Negative 540/49/47 125 (121 to 129)   129 (126 to 132)  
 Positive 200/20/20 116 (111 to 121)   126 (120 to 131)  
MCT4 in stroma    0.673   0.262
 Negative 418/42/44 123 (118 to 127)   127 (123 to 131)  
 Positive 322/27/23 128 (124 to 132)   130 (126 to 133)  
Cytoplasmic beclin-1    0.169   0.566
 Negative 406/46/38 124 (119 to 128)   129 (126 to 132)  
 Positive 334/23/29 121 (118 to 124)   126 (123 to 130)  
Nuclear beclin-1    0.157   0.031
 Negative 666/66/66 125 (121 to 128)   128 (125 to 131)  
 Positive 74/3/1 111 (106 to 115)   136 (132 to 139)  
LC3A in tumor    0.085   0.299
 Negative 669/59/59 126 (122 to 129)   129 (126 to 132)  
 Positive 71/10/8 113 (103 to 122)   124 (115 to 133)  
LC3A in stroma    0.801   0.541
 Negative 687/65/64 125 (122 to 129)   128 (126 to 131)  
 Positive 53/4/3 65 (62 to 68)   66 (64 to 68)  
LC3B in tumor    0.990   0.271
 Negative 475/45/40 125 (121 to 130)   130 (127 to 133)  
 Positive 265/24/27 118 (113 to 123)   125 (120 to 130)  
LC3B in stroma    0.481   0.565
 Negative 688/66/64 125 (122 to 129)   128 (126 to 131)  
 Positive 52/3/3 63 (60 to 66)   64 (62 to 66)  
Cytoplasmic p62 in tumor    0.958   0.528
 Negative 274/26/23 121 (112 to 129)   129 (125 to 133)  
 Positive 466/43/44 126 (122 to 130)   128 (125 to 131)  
Nuclear p62 in tumor    0.210   0.646
 Negative 532/55/51 125 (122 to 129)   128 (125 to 131)  
 Positive 208/14/16 117 (110 to 124)   128 (122 to 133)  
Nuclear p62 in stroma    0.720   0.387
 Negative 512/48/45 126 (122 to 130)   129 (126 to 132)  
 Positive 228/21/22 104 (99 to 109)   124 (118 to 130)  
Tumor phenotype    <0.001   <0.001
 Luminal A 298/15/14 130 (126 to 133)   134 (131 to 137)  
 Luminal B 166/12/11 129 (124 to 134)   130 (124 to 135)  
 HER2 69/11/12 111 (100 to 121)   119 (108 to 130)  
 TNBC 207/31/30 116 (109 to 124)   120 (114 to 126)  
Metabolic status    0.037   0.045
 Warburg type 298/38/36 119 (112 to 126)   124 (119 to 128)  
 Reverse Warburg type 54/6/5 90 (83 to 96)   113 (106 to 121)  
 Mixed type 62/4/6 105 (100 to 111)   112 (99 to 126)  
 Null type 326/21/20 129 (126 to 133)   132 (129 to 136)  
  1. aBNIP3, BCL2/adenovirus E1B 19-kDa interacting protein 3; CAIX, carbonic anhydrase IX; Glut-1, glucose transporter 1; LC3A, microtubule-associated protein 1 light chain 3α; LC3B, microtubule-associated protein 1 light chain 3β; MCT4, monocarboxylate transporter 4; n/a, not applicable; TNBC, triple-negative breast cancer.